Table 3.
Characteristics of Cancer Types, Age, Gender and Clinical Stages in All Studies Included in the Network Meta-Analysis
| Author (Year) | Cancer Types | Age(Year) Median | Gender | Clinical Trial |
|---|---|---|---|---|
| Lee (2018)18 | Ovarian cancer | 56.4±10.8/55.2±8.9 | Female | Phase II |
| Gianni (2018)24 | Breast cancer | 50 | Female | Phase III |
| Park (2017)25 | Breast cancer | 49 | Female | Phase III |
| Shitara (2017)26 | Gastric cancer | >20 | Female/male | Phase III |
| Jain (2016)21 | Breast cancer | 49/50/51 | Female | PhaseII/III |
| Untch (2016)27 | Breast cancer | 49/48 | Female | PhaseIII |
| Rugo (2015)28 | Breast cancer | 57 | Female | PhaseIII |
| Wang (2014)29 | NSCLC | 52.5±13.0/53.8±10.6 | Female/male | NR |
| Awada (2014)30 | Breast | 53/51/50.5 | Female | Phase II |
| Lee (2013)31 | NSCLC cancer | 62/65 | Female/male | Phase IIB |
| Ranade (2013)12 | Breast cancer | 49±12/49.5±10/50±10.5 | Female | Phase II |
| Xu (2013)32 | Gastric cancer | 56/54 | Female/male | NR |
| Zeng (2012)33 | Cervical cancer | 47 | Female | NR |
| Xie (2011)34 | Cervical cancer | 51.5 | Female | NR |
| Gao (2010)35 | NSCLC | 64.5/63.5 | Female/male | NR |
| Guan (2009)36 | Breast cancer | 50 | Female | Phase II |
| Langer 2008)20 | NSCLC | 61.1±10.6/61.5±10.1 | Female/male | Phase III |
| Gradishar (2005)37 | Breast cancer | 53 | Female | Phase III |
| Chen (2003)38 | Breast/NSCLC | 52.1 | Female/male | NR |
Abbreviation: NR, no report.